throbber
Page 1
`
`IN THE UNITED STATES
`PATENT AND TRADEMARK OFFICE
`-------------------
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
`-------------------
`TEVA PHARMACEUTICALS USA, INC.
`Petitioner,
`
`V.
`CORCEPT THERAPEUTICS, INC.
`Patent Owner.
`------------------
`PGR2019-00048
`Patent 10,195,214 B2
`------------------
`
`VIRTUAL DEPOSITION OF DR. LAURENCE KATZNELSON
`May 26, 2020
`
`Reported by:
`ERICA L. RUGGIERI, RPR
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`12
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`1
`
`TEVA1071
`Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc.
`PGR2019-00048
`
`

`

`Page 2
`
`May 26, 2020
`11:02 a.m.
`
`Deposition of DR. LAURENCE
` KATZNELSON, held by Virtual Zoom
` Conference, pursuant to Notice, before
` Erica L. Ruggieri, Registered
` Professional Reporter and Notary
` Public of the State of New York.
`
`12
`
`3
`
`456
`
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`2
`
`

`

`Page 3
`
`A P P E A R A N C E S:
`
`ATTORNEYS FOR TEVA PHARMACEUTICALS USA, INC.:
`STERNE KESSLER GOLDSTEIN & FOX PLLC
` 1100 New York Ave NW, 6th Floor
` Washington DC 20005
` BY: UMA N. EVERETT, ESQ.
`ueverett@skgf.com
`DEBORAH A. STERLING, ESQ., Ph.D.
`dsterling@sternekessler.com
`WILLIAM MILLIKEN, ESQ.
`wmilliken@sternekessler.com
`
`ATTORNEYS FOR CORCEPT THERAPEUTICS, INC.:
`QUINN EMANUEL URQUHART & SULLIVAN LLP f
` 51 Madison Ave, 22nd Floor
` New York, New York 10010
` BY: ERIC STOPS, ESQ.
`ericstops@quinnemanuel.com
`JOHN P. GALANEK, ESQ.
`johngalanek@quinnemanuel.com
`DANIEL WIESNER, ESQ.
`danielwiesner@quinnemanuel.com
`
`12
`
`34
`
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`3
`
`

`

`Page 4
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`DR. KATZNELSON
` L A U R E N C E K A T Z N E L S O N,
` called as a witness, having been
` duly sworn by a Notary Public, was
` examined and testified as follows:
` EXAMINATION BY
` MS. EVERETT:
`Q.
`Good morning,
` Dr. Katznelson.
`A.
`Good morning.
`Q. I am Uma Everett. I am
` from Sterne Kessler Goldstein & Fox.
` I represent Teva Pharmaceuticals and
` I'll be taking your deposition
` today.
`Nice to meet you.
`A.
`Nice to meet you. Thank
`Q.
` you for your time. Dr. Katznelson,
` can you please state your full name
` for the record, please.
`A.
`Laurence Katznelson.
`Q.
`And what is your
` professional address?
`A.
`Stanford Hospital, 875
` Blake Wilbur Road, Stanford,
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`4
`
`

`

`Page 5
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`DR. KATZNELSON
` California 94305-5821.
`Q.
`Have you ever been deposed
` before?
`I have.
`A.
`In what context?
`Q.
`I have been deposed twice,
`A.
` I believe twice, over a number of
` years. Both were cases regarding
` delay in diagnosis of disease so
` they were medical malpractice cases.
`Q.
`Were you an expert in those
` cases?
`In both I was an expert
`A.
` witness, yes.
`Q.
`Have you ever been deposed
` remotely?
`No, this is the first.
`A.
`Q. For all of us. We are
` getting used to it. So I'll just go
` over some basics which you probably
` know about but it's important we are
` both on the same page.
`As you'll note today we have a
` court reporter and she'll take down
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`5
`
`

`

`Page 6
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` my question and your answer. And
` it's more important than ever, even
` in your last ones, that we just give
` each other a pause so that I can end
` my question and you can state your
` answer completely. Mr. Stops may
` have objections through the day and
` we just have to work together to
` make sure everybody's statements are
` coming out and the court reporter
` can take it down.
` And if you need any breaks at
` any time today, please let me know,
` I'm happy to take them. Probably be
` taking them once every hour. I just
` ask that you wait till a question
` has finished, there will be no
` pending questions and then you can
` take a break.
` And you understand that today
` you are under oath?
` A. I do.
` Q. Okay. Is there any reason
` you can't testify truthfully and
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`6
`
`

`

`Page 7
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` accurately today?
` A. No.
` Q. Okay. And we talked about
` today's deposition is being
` conducted remotely, yes?
` A. Yes.
` Q. Are you in your personal
` residence?
` A. I am.
` Q. Can you describe the room
` in which you are sitting?
` A. It's my dining room.
` Q. Are you alone -- sorry, go
` on please if you wanted?
` A. No, no. It's my dining
` room. There's some birds chirping
` outside. It's -- yeah, nothing
` further.
` Q. Are you alone in your room?
` A. I am.
` Q. Do you have any materials
` with you today?
` A. I do. I have the documents
` that the attorneys sent me, my
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`7
`
`

`

`Page 8
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` declaration. That's what I have.
` MR. STOPS: And just for
` clarity, I'll represent that we
` sent a copy of the declaration and
` the exhibits cited in, I believe,
` Exhibit B therein.
` MS. EVERETT: Okay. Terrific.
` Q. Do you have any other
` material in the room with you today?
` A. No. I have my phone with
` me, that's it.
` Q. Are you using your phone to
` communicate with anyone?
` A. No. I -- no, it's really
` just for my son if he has to reach
` me. He just want back to school in
` Boston. So if he needs any urgency,
` that's the only reason I have it on
` now.
` Q. How are you using the video
` platform now? Are you on a
` computer, a laptop computer?
` A. I'm on my Mac laptop on
` Zoom.
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`8
`
`

`

`Page 9
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` Q. Are you speaking with your
` counsel in any form other than your
` Mac laptop?
` A. No, I'm not.
` Q. Did you prepare for today's
` deposition?
` A. I did.
` Q. What did you do to prepare?
` MR. STOPS: And I'll object to
` the extent the question is seeking
` attorney-client communications. If
` you want to ask him a more specific
` question, that might not be
` objectionable.
` MS. EVERETT: What did you do
` to prepare is a pretty basic
` question, Eric. I'm not asking for
` your words. I'm asking what
` Dr. Katznelson --
` MR. STOPS: His answer could
` start divulging specifically what
` he -- what exactly we talked about.
` You can ask, you know, the basic
` questions so that he doesn't.
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`9
`
`

`

`Page 10
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` Q. Dr. Katznelson, don't
` reveal to me the specifics of what
` you discussed with Mr. Stops or any
` counsel that you met with to
` prepare, but generally what did you
` do to prepare for today's
` deposition?
` MR. STOPS: Objection. Calls
` for attorney-client communications.
` I instruct the witness not too
` answer. You can ask a more
` specific question. You are still
` asking the exact same question,
` what did you do to prepare.
` MS. EVERETT: I told him not
` to tell me about your
` communication. This is a pretty
` basic question. What did you do to
` prepare. Don't tell me about
` privileged communication. But what
` did you do. You are seriously
` instructing him not to answer?
` MR. STOPS: I guess I'm not
` sure what your question is. You
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`10
`
`

`

`Page 11
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` can ask him who, when, how long,
` what, but this is a completely
` open-ended question so I have a
` problem with the open-endedness of
` it.
` Q. Did you review any material
` to prepare for your deposition
` today, Dr. Katznelson?
` A. I reviewed the documents
` that we discussed that I received,
` including my declaration. I perused
` the patents and label and I have
` discussed this with my attorneys.
` Q. Did you speak to anybody
` besides your attorneys?
` A. I'm sorry, can you be more
` specific? In what capacity?
` Q. In preparation for your
` deposition today.
` A. I'm sorry, you are asking
` if I spoke to other individuals
` regarding the documents?
` Q. Regarding your preparation
` for your deposition today.
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`11
`
`

`

`Page 12
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` A. Oh, no. All my
` conversations have been privileged
` with the attorneys.
` Q. How long did you spend
` reviewing the materials to prepare
` for your deposition today?
` A. I spent a couple days. An
` evening or two reviewing the
` documents and a couple days
` reviewing these with the attorneys.
` Q. About how many hours did
` you prepare for your deposition
` today?
` A. I would say two days, each
` about seven hours and about several
` evenings of about two hours apiece
` approximately.
` Q. Okay. Now, I'm going to
` put in your declaration, which is
` Corcept Exhibit 2058. I'm moving it
` into the marked exhibits folder. So
` you should be able to see it in a
` moment.
` (Exhibit 2058, Declaration of
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`12
`
`

`

`Page 13
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` Dr. Laurence Katznelson, marked for
` identification, as of this date.)
` MR. STOPS: Dr. Katznelson,
` you may either have to click off of
` the folder or back on or refresh
` the page.
` A. Oh, there it is, okay.
` Q. So you can go ahead and
` either review it electronically and
` download. I know you said you have
` some paper versions of the same
` thing.
` A. Yeah, this looks very
` familiar. Okay, I am with you.
` Q. So Exhibit 2058 is the
` declaration that you submitted for
` this post grant review proceeding,
` correct?
` A. Yes.
` Q. And at the end of that is
` an Exhibit C where you have
` listed -- excuse me, Exhibit B I
` believe -- where you've listed all
` the materials you reviewed to
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`13
`
`

`

`Page 14
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` prepare your declaration?
` A. I'm sorry, which section
` are you referring to?
` Q. Exhibit B at the end of
` your declaration.
` A. Oh, Exhibit B, sorry.
` That's at the end of this? What
` page is it on? Can you help me?
` Q. Starts on 82.
` A. 82. Getting there. I wish
` there was a way to go directly to
` that page but. Okay, I see what you
` are referring to, yes.
` Q. In preparation for your
` deposition today, did you review any
` documents that are not listed in
` your Exhibit B?
` A. No.
` Q. In preparing your
` declaration did you review any
` materials that are not listed in
` Exhibit B?
` A. No.
` Q. Can you describe your
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`14
`
`

`

`Page 15
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` educational background for me,
` please?
` A. Sure. So my college I went
` to USC Berkeley, majored in
` genetics. I went to UCLA for
` medical school. After medical
` school I did a residency in internal
` medicine at the University of
` Pennsylvania.
` Following that I went to
` Massachusetts General Hospital for
` my fellowship in endocrinology and
` metabolism where I became board
` certified in endocrinology. I then
` stayed on on research and clinical
` faculty at Mass General Hospital at
` Harvard in the field of
` endocrinology, specializing in
` pituitary endocrine work where I
` became interested in diseases such
` as Cushing's disease.
` In 2004 I moved to be near
` family in the Bay area where I'm at
` Stanford University where I built
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`15
`
`

`

`Page 16
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` the pituitary program, both clinical
` research at Stanford. I am -- in my
` position I'm professor of medicines
` and neurosurgery. I'm also
` associate dean of all the graduate
` medical education so I run all the
` residency and fellowship programs at
` Stanford Hospital. And I maintain
` my interest in clinical and research
` work in pituitary disorders.
` Q. At the end you listed a
` number of roles. Can you state for
` me your current roles?
` A. Sure. One is a clinician
` so I see patients one and a half
` days a week in the clinic where it
` is pretty much focused at this point
` in my career on pituitary diseases
` such as Cushing's disease. That's a
` clinic that's also an educational
` role because the residents and
` fellows and medical students all
` rotate through.
` I have research roles where I
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`16
`
`

`

`Page 17
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` do clinical trials. My background
` is in clinical trials in the realm
` of endocrinology, mostly pituitary
` disease. Now that is the less of my
` career.
` I would say about 10 to
` 15 percent of my time is spent on
` research. And the rest of my time
` is administrative so I was director
` of our endocrinology fellowship for
` ten years and then I was appointed
` as the associate dean of all of the
` residency fellowships, you can just
` call it graduate medical education,
` which takes up about 70 percent of
` my time.
` Another 15 percent, 20 percent
` of the time -- none of this adds up,
` like all of us, 100 percent. It's
` all much more than that. Most of my
` time is spent doing education both
` regionally, nationally and
` internationally in endocrinology. I
` don't do any classroom teaching
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`17
`
`

`

`Page 18
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` these days. Most of my time is
` spent devising curriculum with new
` educational paradigms in
` endocrinology for others.
` Q. So when you described this
` last educational component, who is
` that, who are you educating?
` A. Anybody. Well, physicians,
` not anybody. Physicians.
` Endocrinologists. I do a lot work
` with the Endocrinology Society --
` Endocrine Society; for example,
` developing educational tools. I do
` a lot of medical rounds. I do a lot
` of regional, national and
` international lectures on pituitary
` diseases, mostly for society work
` such as I spoke with the END -- the
` Endocrine Society in different
` countries such as India, Indian
` Endocrine Society and -- yeah.
` Q. Okay. And so you'd
` estimate that's about 10 to
` 15 percent of your time?
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`18
`
`

`

`Page 19
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` A. That's a guesstimate.
` Q. Okay. Do you do any
` consulting work?
` A. I do. I consult for
` several medical companies.
` Q. Do you consult for Corcept
` aside from your participation in
` this post grant review?
` A. I have worked with Corcept.
` I have consulting. I believe I did
` brief advisory board consulting for
` them some years ago. I have done
` other work for Corcept as well.
` Q. What years were you working
` on an advisory board for Corcept?
` A. I believe it was -- I'm not
` sure, it was around the time that
` the seismic, that's a pivotal study,
` was done. It was brief. Most of my
` work with Corcept has been as a
` co-investigator. I was
` co-investigator with a little study,
` the seismic study. I have two times
` now spoken to their sales force to
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`19
`
`

`

`Page 20
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` discuss basic approaches to
` Cushing's disease and have been paid
` for those efforts. One was in the
` past year.
` Q. How much -- you've done --
` strike that.
` You've worked with Corcept
` sales force twice you said?
` A. I spent two two-hour
` sessions, about two-hour sessions,
` discussing how to -- teaching new
` salespeople how to approach
` Cushing's disease and how to speak
` to doctors like me essentially.
` Q. Okay. And you said you
` were paid for those efforts?
` A. I was.
` Q. How much did you receive?
` A. I know in total for all
` these efforts it was less than
` $10,000. Probably a couple
` thousand -- I mean probably about a
` thousand, 2000 each. I don't
` remember. It was on that realm. It
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`20
`
`

`

`Page 21
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` wasn't too much.
` Q. But you think in total it's
` under 10,000?
` A. Oh, yeah.
` Q. Have you ever testified at
` trial before?
` A. Once.
` Q. What was the nature of that
` trial?
` A. It was a delay in
` diagnosis, it was a malpractice case
` regarding a patient with pituitary
` disease called acromegaly. The
` patient claimed that his diagnosis
` was delayed by -- by this one
` physician and I was retained by that
` physician to side on the defense
` to -- to discuss the case, yes.
` Q. Is this in connection with
` one of the depositions that you
` mentioned a few moments ago?
` A. That would be an additional
` one. So I guess I would have been
` deposed three times. So that would
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`21
`
`

`

`Page 22
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` have been an additional one. It was
` a long time ago but, yes.
` Q. I apologize. Have you ever
` been an expert in a patent case
` before these proceedings?
` A. No.
` Q. Have you ever worked with a
` company to help them seek FDA
` approval to market a drug?
` A. Yes.
` Q. Which company was that?
` A. Ipsen, I-P-S-E-N.
` Q. And what was the indication
` for that drug?
` A. Acromegaly. Acromegaly is
` another type of pituitary disorder
` that causes too much growth hormone
` and people get very large. It's
` very debilitating, sort of like
` Cushing disease and they had a novel
` drug and I went with them to the FDA
` to discuss that.
` Q. What was your role when you
` went with Ipsen to the FDA?
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`22
`
`

`

`Page 23
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` A. I was a medical advisor.
` Q. So what responsibilities
` did you have as a medical --
` A. Answer questions about the
` data and to answer questions about
` the disease. And there were a lot
` of questions.
` MR. STOPS: And, Doctor, I
` assume if this was to the FDA, this
` was a public proceeding, but just
` bear in mind that some of your
` consulting work may be confidential
` to the companies that you did the
` work with. So no one wants you to
` reveal any confidences that you
` have with any specific companies.
` THE WITNESS: Okay.
` Q. Dr. Katznelson, you've
` published a number of articles
` through the years?
` A. Yes.
` Q. Have you ever published
` anything on CYP3A inhibitors?
` A. No.
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`23
`
`

`

`Page 24
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` Q. Have you published anything
` on a drug-drug interaction study?
` A. No.
` Q. Have you ever participated
` in a drug-drug interaction study?
` A. No.
` Q. Have you ever designed a
` drug-drug interaction study?
` A. No.
` Q. Have you ever been
` consulted on the design of a
` drug-drug interaction study?
` A. No.
` Q. Have you ever been a
` principal investigator on a
` drug-drug interaction study?
` A. No.
` Q. I'm going to refer you back
` to your CV, page 80.
` A. Is there a way to -- let me
` go to each page. Okay, page 80.
` Q. Maybe you can look at it on
` the screen. Maybe you can download
` it and then move through it a little
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`24
`
`

`

`Page 25
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` more easily.
` A. I see it now.
` Q. There is -- I'd like to
` point you to number 12. The Open
` Label Study of the Efficacy and
` Safety of Mifepristone.
` MR. STOPS: What page are you
` on, Counsel?
` MS. EVERETT: Page 80.
` Q. And Dr. Katznelson, are you
` at point 12?
` A. Yes.
` Q. In that study on the top
` line it says, "Katznelson, local
` Stanford PI 5 percent"?
` A. Yes.
` Q. What does it mean to have
` your name at the top of that line?
` A. So this -- this is in a
` section of funding. So this is
` standard presentation on a resumé or
` whenever somebody is doing a
` research. So what this says is on
` this trial which started, I guess
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`25
`
`

`

`Page 26
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` the funding started September 4th,
` 2009, that I was the local PI for a
` multicenter trial. That's what that
` means. Five percent is the minimum
` funding we have, we need for my
` research group to participate in the
` study. So I took the minimum
` funding. So 5 percent would be 5
` percent of my salary assuming that I
` recruited X number of patients.
` Q. And do you know what X
` number of patients were?
` A. For this trial I don't
` remember. I do know that it was
` fewer than we had -- than I had
` planned on. I ended up recruiting I
` believe two patients at this time.
` This is not a financial boom for me
` by any stretch.
` Q. Are you currently treating
` any patients with Cushing's
` syndrome?
` A. Many.
` Q. How many?
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`26
`
`

`

`Page 27
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` A. I have probably seen in the
` course of my career somewhere
` between 200 and 400. Probably an
` average of 300. Right now patients
` with Cushing's syndrome with active
` disease, likely around 30, somewhere
` in there.
` Q. What's your total patient
` case load?
` A. I can't even begin to
` guess. I'm not sure right now. I
` can tell you that each week I see
` three half days a week and each day
` is about ten patients and each week
` I probably see about another new
` patient with Cushing's syndrome,
` call up another few. So my whole
` case load is over a thousand. I'm
` not exactly sure.
` Q. Of the 30 patients you are
` actively seeing on Cushing's, how
` many are currently on mifepristone?
` A. I'm not sure. I'm going to
` guess about two, two right now.
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`27
`
`

`

`Page 28
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` Q. Of the 30 patients how many
` are on ketoconazole?
` A. Three or four.
` Q. How many of the patients
` are on both mifepristone and
` ketoconazole?
` A. None.
` Q. Now, I'm going to ask you
` more about your prescribing habits
` more generally. Well, you said
` you've treated on average maybe 300
` patients with Cushing's syndrome?
` A. Correct.
` Q. And of those about
` approximately how many have you
` treated with mifepristone?
` A. I believe I have treated,
` I'm not sure, I'm going to guess,
` again, I don't keep records like
` that, I believe I have treated
` probably about 15 to 20 patients
` with mifepristone. It's a guess
` though, I'm sorry.
` Q. How many patients have you
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`28
`
`

`

`Page 29
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` treated with ketoconazole?
` A. More like 40, 40 or 50.
` Q. How many patients have you
` treated with both mifepristone and
` ketoconazole?
` A. To the best of my
` recollection, none.
` Q. What are the other drugs
` that you have prescribed besides
` ketoconazole and mifepristone?
` A. There's a number of
` medicines we can use for Cushing's
` syndrome. Another one is
` Metyrapone. Metyrapone is a drug
` that was available in the United
` States under Novartis but has since
` -- Novartis dropped it and it moved
` to France to a company so it's
` harder to obtain. That was a very
` good adrenal blocker for this
` disease.
` I have used Mitotane, which is
` a chemotherapy which I don't like
` using because we use it for adrenal
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`29
`
`

`

`Page 30
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` cancer and patients the question
` quite ill with it, they get fatigued
` and have bone marrow suppression.
` Aminoglutethimide I haven't used in
` a number of years because in my
` hands almost everybody was getting
` rashes and fevers so I was very
` concerned about the safety component
` of that drug.
` There's another drug which is
` FDA approved now, pasireotide,
` Signifor, which I have stopped using
` in the recent past.
` There's one other drug called
` cabergoline, which is a dopamine
` type of agent which is not FDA
` approved for this use but in this
` handful of patients it can be used
` for it and I have used that as well.
` Q. Could you say that again?
` A. Cabergoline,
` C-A-B-E-R-G-O-L, as in Larry, -I-N,
` Nancy, -E.
` Q. You said that is not FDA
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`30
`
`

`

`Page 31
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` approved for use in Cushing's?
` A. Correct. There's only a
` couple of drugs which are FDA
` approved for Cushing's.
` Q. When do you choose to use
` this cabergoline drug on Cushing's?
` A. Usually -- there's only two
` drugs FDA approved so -- actually
` now three drugs. So there -- these
` other medications, including
` ketoconazole, are not FDA approved
` in the United States for this use.
` But like ketoconazole, cabergoline
` is oral, it has a pretty
` straightforward action, it's usually
` well tolerated, and it's usually
` used second, third or fourth line
` medical therapy in order to try to
` control the disease. There's some
` reasons to think that in a woman who
` has Cushing's syndrome and is
` pregnant it may be a nice option to
` use because of the safety profile
` but otherwise it's not used very
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`31
`
`

`

`Page 32
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` much.
` Q. So you said earlier that
` there were two FDA approved drugs
` for Cushing's?
` A. There are actually now
` three. Just recently there was a
` new one, Isturisa was approved. The
` two drugs that have been approved up
` till this one was Korlym, that's the
` subject of today, and Signifor.
` It's a Novartis preparation.
` There's a somatostatin analog called
` pasireotide and that drug is also
` FDA approved. And then there's a
` new one the last couple of months.
` Q. So there are certain
` instances in which to appropriately
` treat your patients you think you
` prescribe medicines that have not
` been approved for use in Cushing's?
` A. Correct.
` Q. In your declaration, and I
` think you said this on paragraph 37
` if you want to refer to it, I think
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`32
`
`

`

`Page 33
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` you said, "Given the high potential
` for interaction it's the
` prescriber's responsibility to be
` knowledgeable about" the known and
` unknown -- excuse me. Start that
` over. Start that again.
` In paragraph 37 of your
` declaration you've said, "Given high
` potential for interaction, it's the
` prescribers responsibility to be
` knowledgeable about both known and
` potential drug-drug interactions and
` to adjust his or her prescribing
` practices appropriately."
` A. Right. Correct.
` Q. And you agree with that
` statement today?
` A. Yes.
` Q. What do you do as a
` prescribing physician to be
` knowledgeable about those drug-drug
` interactions?
` A. Well, I do everything I can
` to stay up to date and that includes
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`33
`
`

`

`Page 34
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` DR. KATZNELSON
` reading, you know, journal articles
` that come out on this subject,
` attending conferences. I write a
` number of articles so that also
` pushes me to catch up on what is new
` with potential consequences of drug
` use, whether it's monotherapy or in
` combination. I attend meetings. I
` also when medical science liaisons
` for companies come to my office and
` they tell me -- one of the things I
` want to get out of them is what's
` new, what's understood. So I do
` everything in my power to stay up to
` date with what we know about drug
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket